Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075953 · ClinicalTrials.gov registry record · Phase 2
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
A Phase 2 study of Ductal Carcinoma In Situ, sponsored by QuantumLeap Healthcare Collaborative.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06075953: Recruiting Phase 2 study of Ductal Carcinoma In Situ, sponsored by QuantumLeap Healthcare Collaborative.
NCT06075953 is a Phase 2 study of Ductal Carcinoma In Situ that is actively recruiting participants, run by QuantumLeap Healthcare Collaborative. The registered enrollment target is 400 participants, above the 231-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06075953, a Phase 2 study of Ductal Carcinoma In Situ, is actively recruiting participants, sponsored by QuantumLeap Healthcare Collaborative.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Primary Outcome
Fraction of patients remaining on active surveillance at 7 months compared to control
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole
- DRUG Exemestane
- DRUG Anastrazole
- DRUG Testosterone + Anastrazole
Study Locations (20)
California
- Berkeley Outpatient Center - Berkeley
- City of Hope -Duarte Cancer Center - Duarte
- City of Hope - Lennar Foundation Cancer Center - Irvine
- UCLA - Los Angeles
- UCSF - San Francisco
- City of Hope - South Pasadena
- John Muir Health - Walnut Creek
Minnesota
- Maple Grove Cancer Center - Maple Grove
- Hennepin Healthcare -Minneapolis - Minneapolis
- University of Minnesota - Minneapolis
- Health Partners - Frauenshuh Cancer Center - Saint Louis Park
- Health Partners - Regions Hospital - Saint Paul
New York
- Mount Sinai Union Square - New York
- Mount Sinai Chelsea - New York
- Mount Sinai West - New York
- Icahn School of Medicine at Mount Sinai - New York
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
New Jersey
- Englewood Hospital and Medical Center - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-02-17 |
| Est. Completion | 2033-11 |
| Phase | Phase 2 |
What NCT06075953 shows while recruiting
NCT06075953 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 231-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 5 interventions - of which Tamoxifen is the first listed.
NCT06075953 names 20 study sites across 7 states, led by California, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06075953 about?
NCT06075953 is a clinical study titled "DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment". The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or ...
What is the current status of trial NCT06075953?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2024-02-17. Estimated completion is 2033-11.
What conditions does trial NCT06075953 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ.
What interventions are being tested in trial NCT06075953?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole (DRUG), Exemestane (DRUG), Anastrazole (DRUG), Testosterone + Anastrazole (DRUG).
Who is sponsoring clinical trial NCT06075953?
This trial is sponsored by QuantumLeap Healthcare Collaborative, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075953 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Carcinoma In Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06075953's enrollment target sits among peer trials
400 3rd of 15 higher than 13 of 15 other Ductal Carcinoma In Situ trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ductal Carcinoma In Situ trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Ruxolitinib for Premalignant Breast Disease
ACTIVE NOT RECRUITING · Phase 2
-
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
RECRUITING
-
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
RECRUITING · NA
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI